Caution Notice:
It has come to our notice that certain fraudulent individuals or entities are misusing our Company’s name and TCI’s registered trademarks by promoting and offering for sale regulated and hazardous chemical substances, including Potassium Cyanide, through online platforms like YouTube. We hereby categorically clarify that TCI has no association or connection whatsoever with the products being displayed or sold in these or similar videos. These products have been falsely represented as being associated with TCI, and the unauthorized use of our trademark and brand name is both illegal and misleading. TCI Chemicals is a responsible global organization committed to adhering to all applicable international and domestic regulatory frameworks. We do not manufacture, distribute, or engage in the sale of regulated chemical substances in India or in any other jurisdiction unless specifically authorized by the relevant laws and regulatory agencies. All our operations and offerings are governed by stringent safety, quality, and compliance protocols in accordance with applicable laws. Further, TCI Chemicals markets and sells its products exclusively through its official website and authorized distributors. We do not sell, endorse, or supply our products through any third-party platforms, unauthorized agents, or resellers. Any individual or organization purchasing products outside these official channels does so at their own risk, and TCI disclaims all responsibility and liability for any consequences arising therefrom. Members of the public, customers, and partners are strongly advised to exercise caution and conduct due diligence before engaging in any transactions involving products claiming association with TCI Chemicals. The official list of our authorized distributors is publicly available and may be accessed at: https://www.tcichemicals.com/IN/en/distributor/index. We are currently pursuing appropriate legal remedies against those misusing our brand, and we reserve all rights available to us under applicable intellectual property and criminal laws. If you become aware of any such fraudulent activity or require clarification, you may reach out to us at: Sales-IN@TCIchemicals.com. Your vigilance and cooperation are essential in safeguarding the public interest and protecting the integrity of the TCI brand.
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 5104-49-4 | Product Number: F0371
Flurbiprofen
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 2-(2-Fluorobiphenyl-4-yl)propionic Acid
Product Documents:
| Size | Unit Price | Hyderabad | Japan* | Quantity |
|---|---|---|---|---|
| 5G |
₹5,000.00
|
Contact Us | 5 |
|
| 25G |
₹11,600.00
|
2 | 21 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | F0371 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__5H__1__3FO__2 = 244.27 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 5104-49-4 |
| Reaxys Registry Number | 2054451 |
| PubChem Substance ID | 87570142 |
| SDBS (AIST Spectral DB) | 19990 |
| Merck Index (14) | 4199 |
| MDL Number | MFCD00079303 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 113.0 to 118.0 °C |
| Solubility in Methanol | almost transparency |
Properties (reference)
| Melting Point | 113 °C |
| Solubility in water | Slightly soluble |
| Solubility (soluble in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H301 : Toxic if swallowed. H315 : Causes skin irritation. H319 : Causes serious eye irritation. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | DU8341000 |
Transport Information:
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | III |
Application
Flurbiprofen: A Racemic Non-Selective and Non-Steroidal Anti-Inflammatory Drug (NSAID)
Flurbiprofen is a racemic non-selective and non-steroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid (2-APA) class, such as ibuprofen [I0415], (S)-ibuprofen [I0549], (±)-naproxen [M1220] and (S)-naproxen[M1021]. Only (S)-flurbiprofen [CAS: 51543-39-6] inhibited prostaglandin biosynthesis in vitro. Therefore, (S)-flurbiprofen has been shown to have both antiinflammatory and antinociceptive effects, whereas (R)-flurbiprofen [CAS: 51543-40-9] is antinociceptive but not antiinflammatory. In 2000s, some studies have shown that (R)-flurbiprofen is a potent reducer of levels of β-amyloid (Aβ). Hence, (R)-flurbiprofen had been under development for the treatment of Alzheimer's disease; however this development was discontinued in 2008. (The product is for research purpose only.)
References
- Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases
- Flurbiprofen (a review)
- New insights into the site and mode of antinociceptive action of flurbiprofen enantiomers (a review)
- NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
- Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease (a review)
- Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease (a review)
- Fluorescent Dye Cocktail for Multiplex Drug￢Site Mapping on Human Serum Albumin
- High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE
- Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels
- Characterizing a drug's primary binding site on albumin
- Structural basis of the drug-binding specificity of human serum albumin
ApplicationBinding of Flurbiprofen to Human Serum AlbuminFlurbiprofen is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site II on HSA. Those were confirmed using our ibuprofen with Surface Plasmon Resonance (SPR) and a method using fluorescent probes. 【SPR】Dose responses of flurbiprofen to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
＜Assay condition＞ Sensor Chip: Series S Sensor Chip CM5, Immobilization: HAS (Amine Coupling method), Buffer : 5%DMSO in PBS. ＜Result＞ “Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of flurbiprofen to HSA was confirmed. 【Method using fluorescent probes】The drug biding site of flurbiprofen was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.
＜Assay condition＞ Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Flurbiprofen: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140). ＜Result＞ As shown in upper diagram, inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II by flurbiprofen was confirmed. And also, little or extremely weak inhibition against binding of dansylamide which is fluorescent probe for site I was confirmed. In these ways, our flurbiprofen can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.References
PubMed Literature
Articles/Brochures
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.